At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 3,258 enrolled
Drug / intervention
CHIKV VLP/adjuvant +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
In Brief
A Phase 3 clinical trial evaluating CHIKV VLP/adjuvant and Placebo for Chikungunya Virus. Completed, enrolled 3,258 participants across 47 sites.
Detailed Summary
The goal of this multi-center, randomized, double blind, placebo controlled study is to evaluate the safety and immunogenicity of PXVX0317 (CHIKV VLP vaccine) in healthy adult and adolescent subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChikungunya Virus
CountriesUnited States
CollaboratorsEmergent BioSolutions
Timeline
Phase 3CompletedFinished
20222023202420252026
Enrollment StartSep 2021
First PostedOct 2021
Primary CompletionApr 2023
TodayJul 2026
First PostedOct 8, 2021
Enrollment StartSep 29, 2021
Primary CompletionApr 3, 2023
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 4.7 years ago
Interventions
CHIKV VLP/adjuvantbiological
CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%
Placebobiological
Placebo is comprised of formulation buffer